文献速递系统性红斑狼疮

中国系统性红斑狼疮患者缓解率及其对损伤和生活质量的影响

Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus.
PubMed 文献 · Ann Rheum Dis · 2017-04-21

研究纳入769例中国SLE患者,依据欧洲共识标准评估缓解状态。末次随访时临床缓解占33.7%、完全缓解占36.4%,持续≥5年临床和完全缓解分别占8.3%和16.8%。持续缓解≥5年者SDI增量显著更低且SF36与LupusPRO评分更高。

要点

  • 末次随访临床缓解33.7%、完全缓解36.4%,持续≥5年缓解约四分之一。
  • 持续缓解≥5年者SDI增量0.17±0.53,显著低于未缓解者0.67±1.10。
  • 持续缓解≥5年与SF36及LupusPRO总分显著更高相关。

核心结论

  • 持续性缓解可在约四分之一的SLE患者中实现。
  • 缓解≥5年的患者损伤累积显著更少且生活质量更好。
  • 长期缓解可作为SLE结局评估的合适标准。

研究设计与样本

  • 研究纳入符合≥4项ACR标准且满足欧洲共识缓解定义的SLE患者。
  • 共769例SLE患者(92%女性;年龄46.4±14.6岁;SLE病程12.6±8.1年)。
  • 比较缓解≥5年与未缓解患者前5年SDI增量,并用SF36和LupusPRO评估生活质量。

主要发现

  • 末次随访临床缓解259例(33.7%),完全缓解280例(36.4%)。
  • 临床和完全缓解持续≥5年分别64例(8.3%)和129例(16.8%)。
  • 缓解≥5年者更年长,肾脏受累、白细胞减少或血小板减少的患病率显著更低。
  • 缓解≥5年者中53例(6.9%)停用所有药物包括HCQ(无药状态)。
  • 持续缓解≥5年但停药(除外HCQ)者SDI增量0.17±0.53,显著低于未缓解者0.67±1.10(p<0.001)。

关键数值与推荐

  • 缓解定义采用欧洲共识标准(完全/临床缓解±免疫抑制药物)。
  • SDI增量比较对象为缓解≥5年与未缓解患者的前5年变化。
  • 持续缓解≥5年但停药(除外HCQ)者SDI增量0.17±0.53 vs 未缓解者0.67±1.10,p<0.001。

临床怎么用

  • 可将持续缓解≥5年作为SLE长期结局评估的合适标准。
  • 对达到持续缓解的患者,关注损伤累积减少和生活质量改善的潜在获益。
  • 部分持续缓解患者可停用所有药物包括HCQ,但需结合个体情况评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To study the prevalence of remission and its effect on damage and quality of life (QOL) in Chinese patients with systemic lupus erythematosus (SLE). METHODS: Patients who fulfilled ≥4 American College of Rheumatology criteria for SLE were identified. Their remission status at last clinic visits was determined by the European consensus criteria (complete/clinical remission ± immunosuppressive drugs). The increase in SLE damage index (SDI) in the preceding 5 years was compared between patients who were and were not in remission for ≥5 years. QOL of patients as assessed by the validated Chinese version of the Medical Outcomes Study Short-Form-36 (SF36) and the LupusPRO was also compared between the remission and non-remission groups by statistical analysis. RESULTS: 769 SLE patients were studied (92% women; age: 46.4±14.6 years; SLE duration: 12.6±8.1 years). At last visit, clinical remission was present in 259 (33.7%) patients and complete remission was present in 280 (36.4%) patients. Clinical and complete remissions for ≥5 years were achieved in 64 (8.3%) and 129 (16.8%) of the patients, respectively. Patients remitted for ≥5 years were older, and had significantly lower prevalence of renal involvement, leucopenia or thrombocytopaenia. Fifty-three (6.9%) patients in remission ≥5 years were taken off all medications, including hydroxychloroquine (HCQ) (drug-free). Patients who remitted for ≥5 years but off-therapy (except HCQ) had significantly less SDI increment than those who did not remit (0.17±0.53 vs 0.67±1.10; p<0.001). Among 453 patients who had QOL assessment, remission for ≥5 years was associated with significantly higher SF36 and the total health-related scores of the LupusPRO. CONCLUSIONS: Durable remission can be achieved in a quarter of patients with SLE. Patients with remission for ≥5 years have significantly less damage accrual and better QOL. Prolonged remission is an appropriate criterion for outcome assessment in SLE.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Mok CC, Ho LY, Tse SM, et al. Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus. Ann Rheum Dis. 2017. PMID: 28432050. doi:10.1136/annrheumdis-2016-210382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。